
Areas of Expertise
Conditions I Treat
- Breast cancers and conditions
My Specialties
- Antibody therapy
- Immunotherapy
- Targeted therapy
Get to Know Me
I am a medical oncologist with a practice devoted to treating people with breast cancer.
I chose to focus on oncology because cancer is an enormous human problem and I wanted to help people who are affected by it. It has been my long-term desire to translate scientific discoveries into ways to treat disease and alleviate suffering.
Read more
My laboratory and clinical research both focus on developing new treatment strategies against breast cancers that become resistant to standard treatments. I research the molecular factors that play a role in resistance in order to identify targets that may lead to new treatments.
I am fortunate to work with an exceptional team of physicians and scientists who share my goal of eradicating breast cancer. Together, we are exploring several exciting ways of treating this disease.
Our research includes novel therapies that target the biological factors that make cancers grow. We are studying new inhibitors that block pathways that facilitate breast cancer growth or drug resistance. We are also investigating treatments that can deliver therapy specifically to cancer cells as well as antibody drug conjugates — hybrid drugs that make use of immunotherapy and chemotherapy — which will enable more targeted therapy.
I'm a breast medical oncologist, which is a cancer doctor who specializes in breast cancer.
- Naddisy Foundation Chair in Breast Cancer Research at Memorial Sloan Kettering
Conditions I Treat
- Breast cancers and conditions
My Specialties
- Antibody therapy
- Immunotherapy
- Targeted therapy
Education
- MD, Wake Forest University School of Medicine
- PhD, University of North Carolina at Chapel Hill (Biochemistry)
Residencies
- Internal Medicine - New York Presbyterian Hospital
Fellowships
- Hematology/Medical Oncology - Memorial Sloan Kettering Cancer Center
Board Certifications
- Internal Medicine
- Medical Oncology
Awards and Honors
- Castle Connolly: America’s Top Doctor (2025)
- Castle Connolly: Top AAPI Doctor (2024)
- Castle Connolly: America’s Top Doctor (2024)
- Top Doctors New York Metro Area, Castle Connolly (2023)
- Castle Connolly: America's Top Doctors (2023)
Insurance Information
Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.
In Network Coverage Type
PPO
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
HMO, PPO
In Network Coverage Type
HMO, EPO PPO, POS
In Network Coverage Type
PPO, POS, EPO, HMO
Offers a qualified health plan from the Health Insurance Marketplace. Call Emblem to learn more.
In Network Coverage Type
PPO, HMO
In Network Coverage Type
PPO
In Network Coverage Type
HMO, EPO
Offers a qualified health plan from the Health Insurance Marketplace. Call Fidelis to learn more.
In Network Coverage Type
EPO, HMO, PPO, POS
Offers a qualified health plan from the Health Insurance Marketplace. Call Healthfirst to learn more.
In Network Coverage Type
HMO
In Network Coverage Type
PPO
In Network Coverage Type
EPO
In Network Coverage Type
EPO
In Network Coverage Type
Federal Government
In Network Coverage Type
HMO
City Employee Health Plans (Gold and Gold Care)
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
State Government
Don't see your carrier or plan? We can help you understand your coverage.
If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.
If you have questions about insurance, call us at 646-497-9176.
Make an Appointment

Contact and Location
Dr. Chandarlapaty sees patients at one location.






Looking to see a doctor at a different location? See all MSK locations.
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. I work closely with nurse practitioner Bryn Vandermark and nurse Emer Heaney. We combine our expertise to provide comprehensive care to our patients at every step of their cancer journey.
Clinical Trials

Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
Chandarlapaty S, Sawai A, Scaltriti M, Rodrik-Outmezguine V, Grbovic-Huezo O, Serra V, Majumder PK, Baselga J, Rosen N. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell. 2011 Jan 18;19(1):58-71. doi: 10.1016/j.ccr.2010.10.031. Epub 2011 Jan 6. PMID: 21215704; PMCID: PMC3025058.
Toy W, Shen Y, Won H, Green B, Sakr RA, Will M, Li Z, Gala K, Fanning S, King TA, Hudis C, Chen D, Taran T, Hortobagyi G, Greene G, Berger M, Baselga J, Chandarlapaty S. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet. 2013 Dec;45(12):1439-45. doi: 10.1038/ng.2822. Epub 2013 Nov 3. PMID: 24185512; PMCID: PMC3903423.
Toy W, Weir H, Razavi P, Lawson M, Goeppert AU, Mazzola AM, Smith A, Wilson J, Morrow C, Wong WL, De Stanchina E, Carlson KE, Martin TS, Uddin S, Li Z, Fanning S, Katzenellenbogen JA, Greene G, Baselga J, Chandarlapaty S. Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists. Cancer Discov. 2017 Mar;7(3):277-287. doi: 10.1158/2159-8290.CD-15-1523. Epub 2016 Dec 16. PMID: 27986707; PMCID: PMC5340622.
Li Z, Razavi P, Li Q, Toy W, Liu B, Ping C, Hsieh W, Sanchez-Vega F, Brown DN, Da Cruz Paula AF, Morris L, Selenica P, Eichenberger E, Shen R, Schultz N, Rosen N, Scaltriti M, Brogi E, Baselga J, Reis-Filho JS, Chandarlapaty S. Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway. Cancer Cell. 2018 Dec 10;34(6):893-905.e8. doi: 10.1016/j.ccell.2018.11.006. PMID: 30537512; PMCID: PMC6294301.
Razavi P, Dickler MN, Shah PD, Toy W, Brown DN, Won HH, Li BT, Shen R, Vasan N, Modi S, Jhaveri K, Caravella BA, Patil S, Selenica P, Zamora S, Cowan AM, Comen E, Singh A, Covey A, Berger MF, Hudis CA, Norton L, Nagy RJ, Odegaard JI, Lanman RB, Solit DB, Robson ME, Lacouture ME, Brogi E, Reis-Filho JS, Moynahan ME, Scaltriti M, Chandarlapaty S. Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors. Nat Cancer. 2020 Apr;1(4):382-393. doi: 10.1038/s43018-020-0047-1. Epub 2020 Mar 23. PMID: 32864625; PMCID: PMC7450824.
Li Q, Jiang B, Guo J, Shao H, Del Priore IS, Chang Q, Kudo R, Li Z, Razavi P, Liu B, Boghossian AS, Rees MG, Ronan MM, Roth JA, Donovan KA, Palafox M, Reis-Filho JS, de Stanchina E, Fischer ES, Rosen N, Serra V, Koff A, Chodera JD, Gray NS, Chandarlapaty S. INK4 Tumor Suppressor Proteins Mediate Resistance to CDK4/6 Kinase Inhibitors. Cancer Discov. 2022 Feb;12(2):356-371. doi: 10.1158/2159-8290.CD-20-1726. Epub 2021 Sep 20. PMID: 34544752; PMCID: PMC8831444.
Visit PubMed for a full listing of Dr. Chandarlapaty’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedPatient Reviews
Your trust is our main concern
We strive to keep reviews trustworthy, honest and fair. Learn more about our patient experience reviews.
4.8 66 reviews
- 4.8 Provider's Explanations Easy to Understand
- 4.9 Trusts Provider with Care
- 4.9 Provider Listened Carefully
- 4.8 Likelihood of Recommending Provider
Dr Chandarlapaty is a great doctor. He explains everything. He listens to my questions and he answers them. He has been taking care of me and my cancer for almost 5 years.
When I meet someone who develops breast cancer, I will tell them that Dr. Sarat Chandarlapaty is amazing. He is someone you could trust with your care. he pays attention, listens and doesn't convince to do something one way or another, but DEVELOPS a Plan of treatment based on who you are and where you are in your journey. He is not NOT a one protocol fits all. He gives you the pros and the cons. If you want someone who is analytical, yet doesn't leave you out ofthe journey you are on, then he is your man. If there was a way to rate him higher than a 10 out of 10, he deserves it. He may not come across as mushy and warm. He may seem to say very little at first. But once you develop a relationship, you quickly find he is on YOUR side.
Dr, Chandarlapaty is a terrific breast cancer oncologist. He is always aware of all the changes in my health and listens for my input. He is on top of the latest pharma innovations and approvals and is a very lovely person.
I wish every doctor I had was like Dr. Chandarlapaty and his team.
Both the reception desk and provider were both attentive and courteous to my feelings
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Sarat Chandarlapaty discloses the following relationships and financial interests:
-
AstraZeneca
Professional Services and Activities -
Blueprint Medicines
Professional Services and Activities -
Casdin Capital, LLC
Professional Services and Activities -
Daiichi Sankyo
Professional Services and Activities -
eFFECTOR Therapeutics
Equity; Professional Services and Activities -
Eli Lilly and Company
Professional Services and Activities (Uncompensated) -
Encore Medical Education
Professional Services and Activities -
Genesis Therapeutics
Professional Services and Activities
-
Gerson Lehrman Group
Professional Services and Activities -
Novartis
Professional Services and Activities -
Nuvalent, Inc.
Professional Services and Activities -
Odyssey Biosciences
Equity; Fiduciary Role / Position; Intellectual Property Rights -
Prelude Therapeutics
Professional Services and Activities -
SAGA Diagnostics
Professional Services and Activities -
Springer Nature Limited
Professional Services and Activities -
Totus Medicines Inc.
Equity
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org.